I would say, to the extent you eat animals, try to eat nose to tail, which means try to eat all the organs, try to eat the bones, but at least work in liver and bone broth
-SPF
Metabolomics in Clinical Practice: Improving Diagnosis and Informing Management
Disclosures: Janet Chu: Gilead Sciences, Inc.: Grant/Research Support, Nghiem Ha: Nothing to Disclose, Mandana Khalili: gilead sciences: Grant/Research Support, GSK pharmaceuticals: Consultant, Intercept pharmaceuticals: Grant/Research Support, Gilead Sciences Inc: Consultant, Max Goldman: Eli Lilly: Stock - publicly traded company, Novo Nordisk: Stock - publicly traded company, Eli Lilly: Stock - publicly traded company, Madrigal: Stock - publicly traded company, Bilal Hameed: Gilead: Grant/Research Support, Intercept: Grant/Research Support, Pliant: Grant/Research Support, Novo Nordisk: Grant/Research Support, Madrigal: Grant/Research Support, Salix: Grant/Research Support, Mallinckrodt: Advisor, Pleiogenix: Advisor, CLDF: Advisor, Gilead: Consultant, Pioneering Medicine VII Inc: Consultant, Surrozen: Consultant, Pleiogenix: Stock privately held company, Scholars In Medicine: Speaking and Teaching, Rena Fox: Nothing to Disclose 1152 DIFFERENTIAL PROGNOSIS AND IMPACTS OF CARDIOMETABOLIC RISK FACTORS AND ALCOHOL INTAKE IN MASLD AND METALD PATIENTS Young Chang JAE YOUNG JANG 1 Soung Won Jeong 1 , 1 Soonchunhyang University Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD) are distinct yet overlapping conditions that significantly impact liver disease progression and mortality
